Iowa Association of Pathologists Annual Meeting
If you have questions, please email Mary Lyon or call 515-421-4773.
Soft tissue tumors may sometimes present in superficial locations and pose a diagnostic challenge in classification and distinguishing from other more common cutaneous malignancies. Conversely, non-mesenchymal tumors may sometimes simulate a soft tissue neoplasm. Recent interesting and challenging cases from the UNMC dermatopathology service will be presented, highlighting diagnostic clues, tips for use of ancillary studies, and relevant updates from the recent pathology literature.
Pathologists may face diagnostic challenges with difficult or uncommon cases. This lecture will increase the knowledge of learners in identifying soft tissue tumors and delivery methods to improve the quality of care being given to their patients.
- List the criteria for diagnosis of dedifferentiated and transdifferentiated melanoma.
- Recognize cutaneous clear cell sarcoma features and appropriate utilization of ancillary studies to distinguish from melanoma.
- Discuss the clinicopathologic features of mesenchymal tumors with GLI1 gene alterations.
- Recognize the features of pseudomyogenic hemangioendothelioma and utilize the appropriate panel of immunohistochemical stains and molecular testing for diagnosis.
Welcome and Introduction
Bryan Steussy, MD
The College of American Pathologists: Your Professional and Advocacy Home (Non-CME)
Jared Abbott, MD
Interesting Cutaneous Soft Tissue Tumors
Scott R. Lauer, MD
Scott R. Lauer, MD
Director of the Pathology Residency Training Program, University of Nebraska Medical Center
Education and Training
- Fellowship, Saint Louis University School of Medicine
- MD, Saint Louis University School of Medicine
- Residency, Anatomic and Clinical Pathology, Emory University School of Medicine
- Soft Tissue Pathology Fellowship, Emory University School of Medicine
- Dermatopathology Fellow, Emory University School of Medicine
- MD: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS) through the joint providership of Des Moines University (DMU) and the IMS. DMU is accredited by IMS to provide continuing medical education for physicians. DMU designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
- DO: Des Moines University (DMU) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. DMU designates this activity for a maximum of 1.0 AOA Category 2-A credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
- Other healthcare providers: This live activity is designated for 1.0 AMA PRA Category 1 Credit(s)™.
No ineligible company provided financial support for this continuing education activity.
The speaker(s) will disclose if any pharmaceuticals, medical procedures, and devices discussed are investigational or unapproved for use by the U.S. Food and Drug Administration (FDA). The determination of educational content and the selection of speakers is the responsibility of the activity director.
Relevant to the content of this educational activity, the following individual(s) have no conflict(s) with ineligible companies to disclose.
- Scott R. Lauer, MD, Speaker
- Mary Lyon, Activity Director and Planning Committee Member
- Bryan Steussy, MD, Planning Committee Member
The information provided at this activity is for continuing education. It is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The content of each presentation does not necessarily reflect the views of Des Moines University.
- 1.00 AMA PRA Category 1 Credits™
- 1.00 AOA Category 2A
- 1.00 CE Contact Hour(s)